Search
Feed aggregator
AstraZeneca, Daiichi Sankyo Continue Earlier-Line Breast Cancer Push with Phase III Enhertu Win
AstraZeneca, Daiichi Sankyo Continue Earlier-Line Breast Cancer Push with Phase III Enhertu Win 4/30/2024
Novartis, PeptiDream Ink Potential $2.7B Deal to Expand Radioligand Discovery Partnership
Novartis, PeptiDream Ink Potential $2.7B Deal to Expand Radioligand Discovery Partnership 4/30/2024
Prime Medicine Gets FDA Okay for First Trial of Gene Editing Technique
Prime Medicine Gets FDA Okay for First Trial of Gene Editing Technique 4/30/2024
A Takeda Oncology Leader’s Passion Fuels A Patient-First Approach
A Takeda Oncology Leader’s Passion Fuels A Patient-First Approach 4/30/2024
Ono to Buy Deciphera for $2.4B, Looks to Expand Cancer Pipeline and US Footprint
Ono to Buy Deciphera for $2.4B, Looks to Expand Cancer Pipeline and US Footprint 4/29/2024
BMS, Repertoire Ink Potential $1.8B Deal to Find Vaccines for Autoimmune Diseases
BMS, Repertoire Ink Potential $1.8B Deal to Find Vaccines for Autoimmune Diseases 4/29/2024
FDA Approves First Targeted Treatment for WHIM Syndrome
FDA Approves First Targeted Treatment for WHIM Syndrome 4/29/2024
J&J-Partnered Addex Fails Phase II Epilepsy Study, Mulls Future of Candidate
J&J-Partnered Addex Fails Phase II Epilepsy Study, Mulls Future of Candidate 4/29/2024
Bavarian Nordic’s Mpox Vaccine Safe, Effective at Lower Doses: Study
Bavarian Nordic’s Mpox Vaccine Safe, Effective at Lower Doses: Study 4/29/2024
Safety Concerns with MorphoSys’ Blood Cancer Drug Could Mar $2.9B Novartis Buy: STAT
Safety Concerns with MorphoSys’ Blood Cancer Drug Could Mar $2.9B Novartis Buy: STAT 4/29/2024
Pharma R&D ROI Spikes in 2023 as ‘Breakthroughs’ Re-Energize Industry: Report
Pharma R&D ROI Spikes in 2023 as ‘Breakthroughs’ Re-Energize Industry: Report 4/29/2024
What’s Next for Obesity Therapeutics? Higher Quality Weight Loss
What’s Next for Obesity Therapeutics? Higher Quality Weight Loss 4/29/2024
As Autism Cases Rise, Biopharma Springs Into Action
As Autism Cases Rise, Biopharma Springs Into Action 4/29/2024
5 Mid-Stage ALS Drugs to Watch
5 Mid-Stage ALS Drugs to Watch 4/29/2024
Opinion: Larimar Could Compete with Biogen in Friedreich’s Ataxia
Opinion: Larimar Could Compete with Biogen in Friedreich’s Ataxia 4/29/2024
AbbVie Raises 2024 Profit Outlook, Reports Strong Q1 Sales for Skyrizi and Rinvoq
AbbVie Raises 2024 Profit Outlook, Reports Strong Q1 Sales for Skyrizi and Rinvoq 4/26/2024
Pfizer Secures FDA Approval for Hemophilia B Gene Therapy, Launches Warranty
Pfizer Secures FDA Approval for Hemophilia B Gene Therapy, Launches Warranty 4/26/2024
Gilead Touts 5% Revenue Jump, Positions for 2024 Growth and Culls Pipeline
Gilead Touts 5% Revenue Jump, Positions for 2024 Growth and Culls Pipeline 4/26/2024
GSK Sues Pfizer and BioNTech Over Alleged COVID-19 Patent Infringement
GSK Sues Pfizer and BioNTech Over Alleged COVID-19 Patent Infringement 4/26/2024
Cigna’s Evernorth to Offer Humira Biosimilar with No Out-of-Pocket Cost
Cigna’s Evernorth to Offer Humira Biosimilar with No Out-of-Pocket Cost 4/26/2024
World Pharma News
- U.S. FDA grants full approval to Pfizer's BRAFTOVI combination regimen in first-line metastatic colorectal cancer
- New antibody-drug conjugate strategy to block HIV infection
- Rhododendron-derived drugs now made by bacteria
- Lung cancer drug offers a surprising new treatment against ovarian cancer
- Researchers identify promising Alzheimer's disease drug target